Sales drive up CogState revenues

By Helen Schuller
Wednesday, 24 August, 2005

Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) has reported revenues of AUD$1.5 million for the financial year ending June 30 2005, nearly three times more than the previous corresponding period, largely through sales to major pharmaceutical companies and research institutions.

The company recorded an increase in sales of its diagnostic product of 434 per cent, up from $192,094 in 2004 to $1 million in 2005.

Cogstate reported a net loss of $2.2 million and at 30 June 2005 had a cash balance of balance of $3.4 million.

Content from other channels on our network

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Five trends tracked for NZ's fresh produce sector

Poultry and egg producers in lockdown as avian flu detected in WA

The Data-Ready Foundation for an AI-Powered Healthcare Future

Innovating chemical dosing & dilution in aged care

A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections

The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention

Mandatory VR violence training for nursing students

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

Accenture acquires Dragos and increases OT cybersecurity offering

GWW to provide recycled water for a Victorian data centre

Valves, data centres and the invisible infrastructure of Australian industry

Sales drive up CogState revenues

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network